

NORTHWEST GYNECOLOGICAL CANCER SYMPOSIUM

DECEMBER 4, 2017
PELTON AUDITORIUM
FRED HUTCH

*Bringing together gynecological researchers from
Washington, Oregon & British Columbia*



PROGRAM

- 8:00am - 8:30am Check-in & Poster Set-up
 8:30am - 8:40am **Welcome: Kiran Dhillon, PhD**, Rivkin Center for Ovarian Cancer

SESSION I: PREVENTION & EARLY DETECTION

- 8:40am - 8:45am **Intro: Charles Drescher, MD**, Swedish Cancer Institute / Fred Hutch
- 8:45am - 9:00am **Garnet Anderson, PhD** (Invited Speaker), Fred Hutch
Women's Health Initiative and LILAC resources for gynecological cancers
- 9:00am - 9:15am **Van Nghiem, PhD**, Fred Hutch
"Look" before you LEEP? An economic evaluation of the Pap see-and-treat strategy for the management of cervical pre-cancer
- 9:15am - 9:30am **Shannon Rush, MD**, U. of Washington
Risk-reducing salpingo-oophorectomy: a single institutional experience in over 500 women at increased risk for ovarian carcinoma
- 9:30am - 9:45am **Jeffrey Krimmel-Morrison, MD**, U. of Washington
Deep sequencing of pap smears reveals low-frequency somatic TP53 mutations in women with and without serous ovarian cancer
- 9:45am - 10:05am **Panel Discussion & QA: Moderator Charles Drescher, MD**
- 10:05am - 10:30am **Coffee Break (B-72/74/76)**

SESSION II: CANCER BIOLOGY & MECHANISMS

- 10:30am - 10:35am **Intro: Rosana Risques, PhD**, U. of Washington
- 10:35am - 10:50am **Denise Galloway, PhD** (Invited Speaker), Fred Hutch
HPV oncoproteins disrupt the repair of DNA damage
- 10:50am - 11:05am **Talayeh Ghezelayagh, MD**, U. of Washington
Gain-of-function and loss-of-function TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations
- 11:05am - 11:20am **Maria Isabel Harrell, PhD**, U. of Washington
Development and implementation of a targeted next generation sequencing methylation panel for the assessment of methylation in ovarian and endometrial cancers
- 11:20am - 11:35am **Dawn Cochrane, PhD**, British Columbia Cancer Agency
The origins of endometriosis associated cancers
- 11:35am - 11:50pm **Aline Talhouk, PhD**, U. of British Columbia
Validation of ProMisE molecular classifier in a large population based series: a new era in endometrial carcinoma diagnosis and treatment
- 11:50pm - 12:10pm **Panel Discussion & QA: Moderator Rosana Risques, PhD**

SESSION III: SHORT POSTER PRESENTATIONS 1

12:10pm - 12:20pm Short poster presentations

12:20pm - 2:00pm **Lunch & Posters (B-72/74/76)**

SESSION IV: CANCER THERAPY

- 2:00pm - 2:05pm **Intro: Elizabeth Swisher, MD**, U. of Washington / Seattle Cancer Care Alliance
- 2:05pm - 2:20pm **Gordon Mills, MD/PhD** (Invited Speaker), Knight Cancer Institute
Systems approach to rational combination therapy
- 2:20pm - 2:35pm **Marta Llauro, PhD**, U. of British Columbia
Proteomic biomarkers of MEK inhibitor resistance in low-grade serous ovarian cancer cell lines
- 2:35pm - 2:50pm **Franz Schaub, PhD**, SEngine Precision Medicine
Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer
- 2:50pm - 3:05pm **Yemin Wang, PhD**, U. of British Columbia
Targeting strategies for small cell hypercalcemic carcinoma of the ovary, hypercalcemic type (SCCOHT)
- 3:05pm - 3:25pm **Panel Discussion & QA: Moderator Elizabeth Swisher, MD**
- 3:25pm - 3:50pm **Coffee Break (B-72/74/76)**

SESSION V: SHORT POSTER PRESENTATIONS 2

3:50pm - 4:00pm Short poster presentations

SESSION VI: IMMUNOTHERAPY

- 4:00pm - 4:05pm **Intro: Nora Disis, MD**, U. of Washington / Fred Hutch
- 4:05pm - 4:20pm **Brad Nelson, PhD** (Invited Speaker), British Columbia Cancer Agency
Tumor infiltrating lymphocyte (TIL) patterns in ovarian & endometrial cancers
- 4:20pm - 4:35pm **Kristin Anderson, PhD**, U. of Washington / Fred Hutch
Engineering immunosuppressive pathways operative within T cells for enhancing adoptive therapy of ovarian cancer
- 4:35pm - 4:50pm **Denise Cecil, PhD**, U. of Washington
Vaccine targeting antigens associated with epithelial to mesenchymal transition in combination with cisplatin significantly inhibits ovarian cancer growth
- 4:50pm - 5:05pm **Christopher Morse, MD**, U. of Washington / Fred Hutch
Adoptive T cell therapy for ovarian cancer: Development of a surgically relevant model
- 5:05pm - 5:25pm **Panel Discussion & QA: Moderator Nora Disis, MD**
- 5:25pm - 5:30pm **Closing Remarks: Kiran Dhillon, PhD**, Rivkin Center for Ovarian Cancer
- 5:30pm - 7:00pm **RECEPTION (B-72/74/76)**

POSTERS

Michael Anglesio, PhD, U. of British Columbia

Advanced methods for cancer detection by vaginal screening: feasibility and assessment of deep sequencing based self-sampling methods

Tara Coffin, U. of Washington

MAGENTA: a large randomized study to define an optimal genetic counseling strategy in women undergoing genetic testing at home for ovarian cancer risk

Jamie Crase, U. of Washington

The central role of advocates on the Stand up To Cancer Ovarian Cancer Research Fund Alliance- National Ovarian Cancer Coalition Ovarian Cancer Dream Team

Soledad Jorge, MD, U. of Washington

Disease course and treatment patterns of unselected patients with ovarian carcinoma and germline BRCA mutations

Toni Jun, PhD, Crown Biosciences Inc.

Establishment and characterization of human ovarian cancer xenograft models using bioluminescence imaging

Marilyne Labrie, PhD, Knight Cancer Institute

Adaptive response of ovarian cancer cells to PARP and DNA damage checkpoint inhibitors

Barbara Norquist, MD, U. of Washington, Seattle, WA

WISP: a surgical prevention study evaluating bilateral salpingo-oophorectomy versus interval salpingectomy and delayed oophorectomy in women with inherited mutations in ovarian cancer susceptibility genes

Marc Radke, U. of Washington

Somatic reversion mutations in hereditary ovarian carcinomas predict platinum sensitivity

Chaoyang Sun, PhD, Knight Cancer Institute

BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency

PLANNING COMMITTEE

Brad Nelson, PhD, British Columbia Cancer Agency

Charles Drescher, MD, Swedish Cancer Institute / Fred Hutch

Elizabeth Swisher, MD, University of Washington / Seattle Cancer Care Alliance

Kiran Dhillon, PhD, Rivkin Center for Ovarian Cancer

Nora Disis, MD, University of Washington / Fred Hutch

Rosana Risques, PhD, University of Washington

SPONSORS



SWEDISH
CANCER INSTITUTE

Extraordinary care. Extraordinary caring™



FRED HUTCH
CURES START HERE™



TESARO™



MERCK

TWINSTRAND™
Biosciences



FOUNDATION
MEDICINE



CrownBio
CONNECTING SCIENCE TO PATIENTS